Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 180 shares at $73.00 ($13K) on 2026-02-18, disclosed to the SEC on 2026-02-20.
Seasonal sale ($13k) by Chief R&D Officer — this insider has traded NKTR in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-01-22 | $138K | — | Filing → |